RGT 018
Alternative Names: RGT-018Latest Information Update: 30 Jun 2023
At a glance
- Originator Regor Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action SOS1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 09 Jun 2023 Regor Therapeutics plan to file an IND application for Cancer
- 14 Apr 2023 Pharmacodynamics data from a preclinical studies in Cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 13 Apr 2023 Preclinical trials in Cancer in China (PO) before April 2023.